Drug Profile

CX 011

Alternative Names: CX-011

Latest Information Update: 24 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CarthroniX
Class Antirheumatics; Small molecules
Mechanism of Action Cytokine receptor gp130 modulators; Interleukin 6 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Osteoarthritis

Most Recent Events

24 Sep 2025 Preclinical development for Osteoarthritis is ongoing in the US (Intra-articular)
24 Sep 2025 CarthroniX plans a phase I/IIa trial for Osteoarthritis (Intra-articular) in quarter four of 2025 (CarthroniX pipeline, September 2025)
31 Mar 2025 CarthroniX, received IND clearance from the US FDA to initiate first-in-human clinical study of CX-011, prior to March 2025 (CarthroniX pipeline, September 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com